Description
A phase 1 Randomized, Single-Centre, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSV¿-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02014-10-01$305,910
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2014-10-01(start date) | $305,910 | — | A phase 1 Randomized, Single-Centre, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate the Safe… |
Related records · 2
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 236-2014-2015-Q3-00060 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $6,583,497 | FY2015 |
| 236-2012-2013-Q2-00468 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $1,360,333 | FY2013 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2014-2015-Q3-00070 · retrieved 2026-11-13.